The QT interval as it relates to the safety of non-cardiac drugs

European Heart Journal, Supplement

Volumn 9, Issue G, 2007, Pages

  Kowey, Peter R ^a   Malik, Marek ^b,c  

^a LANKENAU HOSPITAL   (United States)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c St Paul's Cardiac Electrophysiology   (United Kingdom)

Author keywords

Delayed repolarization; Drug safety; Pro arrhythmia; QT study; QT QTc prolongation; Torsade de pointes

Indexed keywords

EID: 44949260672     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sum047     Document Type: Review

References (21)

1. European Agency for the Evaluation of Medicinal Products (EMEA). ICH Topic S7B: note for guidance on the nonclinical evaluation of the potential for delayed ventricular repolarisation (QT interval prolongation) by human pharmaceuticals. (CPMP/ICH/423/02), November 2005.
2. Food and Drug Administration (FDA). Guidance for industry: E14: clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. October 2005.
3. European Agency for the Evaluation of Medicinal Products (EMEA). ICH Topic E14: note for guidance on the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (CHMP/ICH/2/04). November 2005.
4. Malik M. Errors and misconceptions in ECG measurement used for the detection of drug induced QT interval prolongation. J Electrocardiol 2004;37(Suppl.):25-33.
5. Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN. The QT interval. Prog Cardiovasc Dis 2001;43(Suppl. 1):1-45.
6. Camm AJ. Clinical trial design to evaluate the effects of drugs on cardiac repolarization: current state of the art. Heart Rhythm 2005;2:S23-S29.
7. Malik M. The imprecision in heart rate correction may lead to artificial observations of drug induced QT interval changes. Pacing Clin Electrophysiol 2002;25:209-216.
8. Malik M, Färbom P, Batchvarov V, Hnatkova K, Camm AJ. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart 2002;87:220-228.
9. Batchvarov VN, Ghuran A, Smetana P, Hnatkova K, Harries M, Dilaveris P, Camm AJ, Malik M. QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. Am J Physiol Heart Circ Physiol 2002;282:H2356-H2363.
10. Committee for Proprietary Medicinal Products (CPMP). Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. European Agency for the Evaluation of Medicinal Products, England, London, 1997.
11. Heist EK, Ruskin JN. Drug-induced proarrhythmia and use of QTc-prolonging agents: clues for clinicians. Heart Rhythm 2005;2:S1-S8.
12. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-1022.
13. Joshi A, Dimino T, Vohra Y, Cui C, Yan GX. Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: the role of experimental models. J Electrocardiol 2004;37(Suppl.):7-14.
14. Carlsson L. In vitro and in vivo models for testing arrhythmogenesis in drugs. J Int Med 2006;259:70-80.
15. Liu T, Brown BS, Wu Y, Antzelevitch C, Kowey PR, Yan GX. Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm 2006;3:948-956.
16. Antzelevitch C. Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes. Heart Rhythm 2005;2:S9-S15.
17. Fenichel RR, Malik M, Antzelevitch C, Sanguinetti M, Roden DM, Priori SG, Ruskin JN, Lipicky RJ, Cantilena LR, Independent Academic Task Force. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 2004;15:475-495.
18. Fitzgerald PT, Ackerman MJ. Drug-induced torsades de pointes: the evolving role of pharmacogenetics. Heart Rhythm 2005;2:S30-S37.
19. Belardinelli L, Shryock JC, Wu L, Song Y. Use of preclinical assays to predict risk of drug-induced torsades de pointes. Heart Rhythm 2005;2:S16-S22.
20. Malik M. Detection of drug-induced proarrhythmia: balancing preclinical and clinical studies. Heart Rhythm 2005;2:773-776.
21. Malik M, Hnatkova K, Batchvarov V, Gang Y, Smetana P, Camm AJ. Sample size, power calculations and their implications for the cost of thorough studies of drug induced QT interval prolongation. Pacing Clin Electrophysiol 2004;27:1659-1669.